Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
- View all journals
- Explore content
- About the journal
- Publish with us
- Sign up for alerts
Browse Articles
Author correction: precision targeting of autoantigen-specific b cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor t cells.
- Sangwook Oh
- Aimee S. Payne
Directed evolution of engineered virus-like particles with improved production and transduction efficiencies
Engineered virus-like particles are improved through directed evolution.
- Aditya Raguram
- David R. Liu
Biotech news from around the world
A bacterial neoantigen cancer vaccine.
- Iris Marchal
First proof-of-mechanism for RNA editing in humans
Shot in the arm for biotech fuels, cancer cases in bluebird’s gene therapy trials.
From Bench to Podcast: Ali Shaib
Wasp gut microbes yield beer with extra tang
- Claire Turrell
Virus-like elements
Recent patents relating to retroviruses, transposons and other virus-like elements for use in gene transfer and gene therapy.
LucaProt reveals the diverse global RNA virome
Glucose-responsive insulin for diabetes.
Recent moves of note in and around the biotech and pharma industries.
Who made the mRNA vaccine? Measuring division of labor in therapeutic innovation
To accelerate future vaccine development, understanding the longer-term funding dynamics behind recent successes such as the USA’s Operation Warp Speed and the UK’s Vaccine Taskforce is imperative.
- Henry C. W. Price
- Eoin O’Sullivan
Behind the graduate mental health crisis in science
Survey results identify how scientific research and teaching contribute to the graduate student mental health crisis.
- Carly A. Busch
- Nicholas J. Wiesenthal
- Katelyn M. Cooper
Multimodal scanning of genetic variants with base and prime editing
Thousands of rare oncogene variants are evaluated using multimodal gene editing screens.
- Olivier Belli
- Kyriaki Karava
- Randall J. Platt
Beyond the blood: expanding CAR T cell therapy to solid tumors
Recent clinical trials testing CAR T cells on solid tumors have yielded promising outcomes that can be enhanced with further CAR engineering.
- Carl H. June
Saturation profiling of drug-resistant genetic variants using prime editing
PEER-seq characterizes the drug resistance profiles of thousands of genetic variants.
- Younggwang Kim
- Hyeong-Cheol Oh
- Hyongbum Henry Kim
Amyloid is everywhere, but new treatments could stop the toxic build up
Amyloid deposits are present in the brains of cognitively impaired individuals, but also accumulate throughout the body. Some biotechs aim to keep these misfolded proteins in check to treat a range of diseases, including heart failure, ALS and Alzheimer’s disease.
- Cormac Sheridan
Italy tests first gene-edited vines for winemaking
Europe’s first field trial of gene-edited vines began in northern Italy on 30 September 2024. Developed by EdiVite, a spinoff from the University of Verona, these Chardonnay vines have undergone gene inactivation to enable them to better defend themselves against downy mildew, a major fungal disease. The trial is being conducted on university land, with plans to expand to another site in the Veneto region. Researchers aim to gather initial data by 2025, with the potential for experimental winemaking in 2026.
- Anna Meldolesi
Quick links
- Explore articles by subject
- Guide to authors
- Editorial policies
IMAGES
VIDEO